Momentum is crucial across many walks of life. Not least politics, sports and the economy. However, for rapidly expanding tech firms it is one of the most important KPIs, particularly when it comes to orderflow and ultimately achieving sector dominance. On Tuesday (7th), Kromek certainly did not disappoint. Saying that it “expects to report revenue growth for the full year 2018/19 and EBITDA profit in-line with market expectations.” Implying a strong H2’19, partly aided by £1.5m-£2.0m of shipments which were deferred from H1’19, due to the relocation of US production to a new medical grade, manufacturing facility in Pittsburgh. I guess we shouldn’t be too surprised though, since Kromek has delivered 33% top line CAGR since FY13.
10 May 2019
Trading in line with expectations
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Trading in line with expectations
Kromek Group Plc (KMK:LON) | 6.8 0 0.0% | Mkt Cap: 43.9m
- Published:
10 May 2019 -
Author:
Paul Hill -
Pages:
4
Momentum is crucial across many walks of life. Not least politics, sports and the economy. However, for rapidly expanding tech firms it is one of the most important KPIs, particularly when it comes to orderflow and ultimately achieving sector dominance. On Tuesday (7th), Kromek certainly did not disappoint. Saying that it “expects to report revenue growth for the full year 2018/19 and EBITDA profit in-line with market expectations.” Implying a strong H2’19, partly aided by £1.5m-£2.0m of shipments which were deferred from H1’19, due to the relocation of US production to a new medical grade, manufacturing facility in Pittsburgh. I guess we shouldn’t be too surprised though, since Kromek has delivered 33% top line CAGR since FY13.